Dr. Scott Kahan, Director of the National Center for Weight and Wellness at Johns Hopkins Bloomberg School of Public Health, highlights the importance of new mechanisms of action beyond GLP-1 therapies.

Dr. Scott Kahan, Director of the National Center for Weight and Wellness at Johns Hopkins Bloomberg School of Public Health, highlights the importance of new mechanisms of action beyond GLP-1 therapies. These innovative approaches – targeting muscle, fat, and liver cells – could help people who currently don’t respond to or can’t tolerate existing medications.

View on Linkedin

More Resources

Press Releases

The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next‑Generation Obesity Therapy

Videos

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, emphasizes how Vial’s INHBE siRNA directly impacts the function of adipose tissue to better address cellular hypertrophy and inflammation.

Videos

Obesity expert and researcher, Dr. Lawrence Cheskin MD, discusses how targeting adipose tissue is critical for treating obesity, positioning INHBE siRNA as a promising target to drive quality fat loss.

Connect with us.

Interested in receiving a proposal from Vial? Leave us a message and some of your contact info and we’ll be in touch with you shortly.

Comments

This field is for validation purposes and should be left unchanged.

Name(Required)

Work email(Required)

Phone

Company(Required)

Which best describes you?(Required)

Message

By submitting, you are agreeing to our terms and privacy policy